- POSITIVE
Quarterly Revenue Jupiter Life Line Sep-2026 Quarterly Revenue is Rs 371 Cr which is growth of 13.6% YoY.
- NEGATIVE
Quarterly Net Profit Jupiter Life Line Sep-2026 Quarterly Net Profit is Rs 51 Cr which is growth of -5.8% YoY.
NSE: JLHL | BSE: 543980
Jupiter Life Line Live Share Price Today, Share Analysis and Chart
aboutJupiter Life Line Hospitals Ltd. (JLHL) is a multi-specialty tertiary and quaternary healthcare provider primarily operating in the Mumbai Metropolitan Area (MMA) and western India. The company follows an asset-owned model, where it typically owns th... Read More
289.75-0.15(-0.05%)
106.6K
NSE+BSE Volume
NSE 17 Nov, 2026 3:31 PM
Jupiter Life Line Stock Price Ranges
Day Price Range-0.0% 1 Day return | 289.8 (LTP) 283.2294.8 LowHigh |
|---|---|
Week Price Range-0.8% 1 Week return | 289.8 (LTP) 280.2296 LowHigh |
Month Price Range17.3% 1 Month return | 289.8 (LTP) 233.4296 LowHigh |
52 Week Price Range-1.0% 1 Year return | 289.8 (LTP) 233.4340 LowHigh |
Jupiter Life Line Forecaster - Analyst Share Price Target and Estimates
Revenue forecast
EPS forecast
CURRENT EPS
AVG. ESTIMATE
Consensus Recommendation
6 ANALYST Recommendations
STRONG BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Forecaster
Peers
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Jupiter Life Line quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 371.5 | 339.1 | 321.4 | 300.6 | 327.1 | 290.8 | 280.9 | 277.3 | 282.4 | 247.7 | 254.1 | 238.3 | 233.2 | ||
Operating Exp. | 270.5 | 259.3 | 234.3 | 215.8 | 237 | 210.4 | 201.7 | 201.7 | 203.7 | 183.7 | 188.9 | 173.3 | 168.3 | |
Operating Profit | 94.1 | 69.2 | 78.1 | 75.6 | 78.8 | 67.5 | 72.2 | 67.4 | 69.5 | 55.7 | 56.4 | 57.1 | 58.8 | |
Operating Profit Margin % | 25.82% | 21.05% | 25.01% | 25.95% | 24.96% | 24.30% | 26.36% | 25.06% | 25.43% | 23.26% | 22.98% | 24.76% | 25.89% | |
Depr. | 23.5 | 21.6 | 18.5 | 16.8 | 16.7 | 16.7 | 13.4 | 10.6 | 10.4 | 8 | 7.5 | 7.7 | 7.7 | |
Interest | 9 | 8.1 | 4.2 | 2.7 | 3 | 3 | 4 | 2.7 | 1 | 0.9 | 0.9 | 1 | 8.5 | |
Profit Before Tax | 68.5 | 50.1 | 65.5 | 59.8 | 70.5 | 60.8 | 61.8 | 62.3 | 67.3 | 55 | 59 | 56.2 | 48 | |
Tax | 17.1 | 12.9 | 16.3 | 15.5 | 15.9 | 17.5 | 17.3 | 13 | 17 | 14.3 | 15.9 | 13.9 | 11.9 | |
Net Profit | 51.5 | 37.2 | 49.2 | 44.3 | 54.6 | 43.3 | 44.5 | 49.3 | 50.3 | 40.7 | 43.2 | 42.2 | 36.1 | |
EPS Adj. latest | 1.6 | 1.1 | 1.5 | 1.4 | 1.7 | 1.3 | 1.4 | 1.5 | 1.5 | 1.2 | 1.3 | 1.3 | 1.1 | |
Net profit TTM | 182.1 | 185.3 | 191.4 | 186.6 | 191.7 | 187.4 | 184.7 | 183.4 | 176.3 | 162.2 | 152 | 135.6 | 100.5 | |
Basic EPS TTM | 5.6 | 28.3 | 29.2 | 28.5 | 29.2 | 28.6 | 28.2 | 28 | 26.9 | 24.7 | 23.2 | 20.7 | 15.3 | |
Earnings Transcripts | ||||||||||||||
AI Summary | ||||||||||||||
Results PDF | ||||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Jupiter Life Line Technical Analysis
Jupiter Life Line EMA & SMA
Bullish+8
Bullish8
Bearish0
| 5 Day | 288.1 |
|---|---|
| 10 Day | 284.0 |
| 12 Day | 282.1 |
| 20 Day | 276.3 |
| 26 Day | 274.1 |
|---|---|
| 50 Day | 273.6 |
| 100 Day | 276.3 |
| 200 Day | 277.4 |
Jupiter Life Line Delivery And Volume
Daily Avg. Delivery Volume %
17 Nov, 202655.0%
Week49.8%
Month56.6%
PositiveNeutralNegative
Jupiter Life Line Resistance and Support
289.22
Pivot
| First Resistance | 295.3 |
|---|---|
| Second Resistance | 300.8 |
| Third Resistance | 306.9 |
| First Support | 283.7 |
|---|---|
| Second Support | 277.6 |
| Third Support | 272.1 |
| Day RSI | 66.2 |
|---|---|
| Day MACD | 8 |
| Day MFI | 80.8 |
| Day MACD Signal Line | 5.6 |
Jupiter Life Line Beta
| 1 Month | 0.6 |
|---|---|
| 1 Year | 0.3 |
| 3 Month | 0.5 |
|---|---|
| 3 Year | 0.4 |
Jupiter Life Line Price Change Analysis
↑17.3%
Over 1 Month
LowHigh
233.4296
↓-8.2%
Over 3 Months
LowHigh
233.4324
↑9.2%
Over 6 Months
LowHigh
233.4340
↓-1.1%
Over 1 Year
LowHigh
233.4340
Jupiter Life Line Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| MITUL NITIN THAKKER | Block | Sell | 15 Jul 2026 | 1483.50 | 600,000 | BSE |
| ARVIND RAO RAO KAMINI | Block | Sell | 15 Jul 2026 | 1483.50 | 337,000 | BSE |
| HDFC MUTUAL FUND | Block | Purchase | 15 Jul 2026 | 1483.50 | 600,000 | BSE |
| HDFC MUTUAL FUND | Block | Purchase | 15 Jul 2026 | 1483.50 | 337,000 | BSE |
| ARVIND RAO RAO KAMINI | Bulk | Sell | 15 Jul 2026 | 1483.50 | 337,000 | BSE |
| MITUL NITIN THAKKER | Bulk | Sell | 15 Jul 2026 | 1483.50 | 600,000 | BSE |
| HDFC MUTUAL FUND | Bulk | Purchase | 15 Jul 2026 | 1483.50 | 937,000 | BSE |
| SBI MUTUAL FUND | Bulk | Sell | 13 Nov 2025 | 1497.80 | 2,313,613 | NSE |
| SBI MUTUAL FUND | Bulk | Purchase | 13 Nov 2025 | 1497.80 | 2,313,615 | NSE |
| BRINDHA RAGHAVAN | Block | Sell | 29 Aug 2024 | 1310 | 100,000 | NSE |
Jupiter Life Line Corporate Actions
Jupiter Life Line Dividend history and yield
Jupiter Life Line dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Jupiter Life Line dividend yield over time.
#Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
122 May 2026 | 1 | INTERIM | 22 May 2026 | Equity Share |
204 Jul 2025 | 1 | FINAL | 04 Jul 2025 | Equity Share |
302 Aug 2024 | 1 | FINAL | 02 Aug 2024 | Equity Share |
Jupiter Life Line Board Meetings
Jupiter Life Line past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
123 Oct 2026 | Quarterly Results | - |
231 Jul 2026 | Quarterly Results | - |
315 May 2026 | Quarterly Results, Int. Dividend & Stock Split | - |
430 Jan 2026 | Quarterly Results | - |
507 Nov 2025 | Quarterly Results | - |
Jupiter Life Line Stock Split
Jupiter Life Line stock split details, including announcement, record, and ex-split dates, along with the split ratios
#Ex-Date | Old FV | New FV | Record Date |
|---|---|---|---|
124 Jul 2026 | 10 | 2 | 24 Jul 2026 |
Jupiter Life Line Research Reports
Jupiter Life Line research reports with share price targets, and buy/hold/sell recommendations from top brokers.
# Date | Broker Name | Target | Price When Recommended | Type | Upside | Change Since Recommendation | Links |
|---|---|---|---|---|---|---|---|
| 118 May 2026 | Prabhudas Lilladhar | 1600 | 1328.9 | Buy | 20.4% | -78.2% | |
| 218 May 2026 | Anand Rathi | 1560 | 1328.9 | Buy | 17.39% | -78.2% | |
| 309 Mar 2026 | Prabhudas Lilladhar | 1600 | 1264.9 | Buy | 26.49% | -77.09% | |
| 402 Feb 2026 | Prabhudas Lilladhar | 1600 | 1257.5 | Buy | 27.24% | -76.96% | |
| 510 Nov 2025 | Prabhudas Lilladhar Target | 1800 | 1506 | Buy | 19.52% | -80.76% |
Jupiter Life Line Corporate Filings
Jupiter Life Line BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 12 Nov 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations) | Addition of approximately 40-50 beds to the existing Thane Hospital. | |
| 09 Nov 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure requirements) Regulations 2015. | |
| 29 Oct 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Q2 FY27 Earnings Conference Call - Transcript | |
| 26 Oct 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Audio Link of Analyst/ Investor Conference Call for Q2 & H1 FY27 | |
| 26 Oct 2026 | Jupiter Life Line Hospitals Results Earnings Call for Q2FY27 | Conference Call with Jupiter Life Line Hospitals Management and Analysts on Q2FY27 Performance and Outlook. Listen to the full earnings transcript. |
Jupiter Life Line Documents
Jupiter Life Line Earnings Call
Jupiter Life Line earnings calls, including management commentary and AI-generated summaries.
| Date | Title | Links |
|---|---|---|
| 29 Oct 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | |
| 26 Oct 2026 | Jupiter Life Line Hospitals Results Earnings Call for Q2FY27 | AudioVideo |
| 07 Aug 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | |
| 03 Aug 2026 | Jupiter Life Line Hospitals Results Earnings Call for Q1FY27 | AudioVideo |
| 21 May 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript |
Jupiter Life Line Annual Reports
Jupiter Life Line financials, including annual results, balance sheets, and cash flow statements.
Jupiter Life Line Investor Presentations
Jupiter Life Line investor presentations, including business updates, financial insights, and strategic initiatives.
| Date | Report Title | Links |
|---|---|---|
| 23 Oct 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Announcement under Regulation 30 (LODR)-Investor Presentation | |
| 31 Jul 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Announcement under Regulation 30 (LODR)-Investor Presentation | |
| 15 May 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Announcement under Regulation 30 (LODR)-Investor Presentation | |
| 31 Jan 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Announcement under Regulation 30 (LODR)-Investor Presentation | |
| 30 Jan 2026 | Jupiter Life Line Hospitals Ltd - 543980 - Announcement under Regulation 30 (LODR)-Investor Presentation |
Jupiter Life Line - Company Profile
Jupiter Life Line Management Structure
Jupiter Life Line management structure with salaries, total experience, and qualifications.
Jupiter Life Line Board of Directors
Jupiter Life Line Board of directors with salaries, total experience, and qualifications.
Website: www.jupiterhospital.com
About the company - Business Profile
Jupiter Life Line Hospitals Ltd. (JLHL) is a multi-specialty tertiary and quaternary healthcare provider primarily operating in the Mumbai Metropolitan Area (MMA) and western India. The company follows an asset-owned model, where it typically owns the underlying land and hospital infrastructure. JLHL operates under the "Jupiter" brand, providing specialized medical services across various specialties, including cardiology, oncology, neurosciences, and orthopaedics.
Key Points
Key Facts
- Founded Year: 2002
- Headquarters: Thane, Maharashtra, India
- Stock Listing: Listed on BSE (Code: 543980) and NSE (Symbol: JLHL)
- Market Capitalization: ₹10,447.62 crore (as of March 31, 2025)
Operations and Resources
- Existing Facilities: Operates three major hospitals located in Thane, Pune, and Indore.
- Bed Capacity: As of December 31, 2025, the total existing operational bed capacity was 1,048 beds.
- Expansion: A new 500-bed facility in Dombivli was operationalized ahead of schedule, with the OPD starting in early February 2026 and full clinical operations on February 18, 2026. Phase I of this project involved 300 fit-out beds and 200 operational beds.
- Future Pipeline: Projects are underway in Pune South (Bibwewadi) (500 beds, expected CY28) and Mira-Bhayandar (300 beds, expected CY29), aiming for a total capacity of approximately 2,500 beds.
Business Model and Performance
- Revenue Model: JLHL focuses on a high-margin "Patient First" model with a significant portion of revenue derived from self-pay and insured patients rather than government schemes.
- Geographical Presence: Concentrated in the high-growth markets of Maharashtra and Madhya Pradesh.
Revenue and Financial Highlights (FY 2024-25)
- Revenue from Operations: ₹1,245.40 crore (Annual FY25)
- EBITDA: ₹296.60 crore (Margin: 23.5%)
- Profit After Tax (PAT): ₹193.50 crore (Margin: 15.3%)
- 9MFY26 Performance: For the nine months ended December 31, 2025, revenue from operations reached ₹1,063.8 crore, a 15.3% YoY increase. EBITDA for the same period was ₹254.0 crore.
Operational Metrics (9MFY26)
- ARPOB (Average Revenue Per Occupied Bed): ₹66,800 (vs ₹59,000 in 9MFY25)
- Average Occupancy Rate: 61.9% (reflecting expanded capacity)
- ALOS (Average Length of Stay): 3.85 days
- Payor Mix: Insurance (55.7%), Self-Pay (43.2%), and Government Schemes (1.1%).
Key Products and Technology
- Diagnostic Advancement: Utilization of mammography with tomosynthesis for early breast cancer detection.
- Therapeutic Systems: Radiation therapies including 3DCRT, IMRT, and SBRT delivered through EBRT or Internal Radiation Therapy.
- Automation: Automated systems for scheduling and calibration across connected medical analyzers.
Sustainability and Strategic Initiatives
- Clinical Talent: Focus on a "doctor-led" model to ensure high-quality quaternary care.
- Strategic Growth: Aggressive expansion in the western region of India, targeting high-density residential hubs for new greenfield hospitals.
- Labour Code Impact: A one-time statutory impact of ₹6.4 crore was noted in Q3FY26 due to New Labour Code changes.
References
